President Trump’s temporary ban on immigration from seven predominantly Muslim countries could hamper bioscience research, according to Hakim Djaballah, a biotech consultant in New York.

Djaballah, who works in the fields of aging, infectious disease, and oncology, is on the board of the Pasteur Institute of Iran, and he’s concerned that mounting tensions between the US and countries affected by the 90-day ban — Iran, Iraq, Libya, Somalia, Sudan, Syria, and Yemen — might impede scientific progress. Here’s what he had to say, edited for clarity:

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Here’s also why a lot of this is hyperbolic. Companies like Pfizer have shut down huge numbers of their domestic labs and used the savings to buy videoconferencing systems. So the lab protocol gets written in USA sent Pfizer Transylvania Laboratories, and the results are sent back to PFE. Everything is done electronically without the infrastructure of an American laboratory. No muss, no fuss, a weekly videoconference takes the place of live meetings.

  • For at least 30 years talented American chemists have been laid off in favor of H1b’s who come in at the bottom end of the salary range and keep America’s jobs in perpetuity. Maybe now things will be looking up for the American Pharma lab worker.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy